“
Yevgeny Demkivsky Author of news Mezha.media and GIK. I write about technologies, cinema and games. Perhaps about games with a little more passion.
“The next big milestone is the beginning of clinical trials, the introduction of these drugs into the human body. We are already approaching that,” Mrdok said.
Isomorphic Labs emerged in 2021 as a daughter of DeepMind after a breakthrough of Alphafold, a system that accurately involves protein structure. The latest version, Alphafold 3, allows you to model the interaction of proteins with DNA, medicines and other molecules, which has made it useful for the development of new drugs.
In 2024, the company signed contracts for joint research with Novartis and Eli Lilly pharmaceuticals. And in April 2025, she raised $ 600 million in investments under the guidance of Thrive Capital.
Isomorphic Labs is working on creating a platform that will combine the experience of pharmacists with machine learning capabilities. The company not only supports partners’ projects, but also initiates the development of medicines in the fields of oncology and immunology. After the early stages of the test, she plans to licensing her development.
Murdock believes that the use of AI will not only accelerate and reduce the cost of development, but also significantly increase the chances of success in clinical trials. In the future, the team seeks to automate the process: to determine the disease and with the help of AI to receive the finished design of the drug.
”, – WRITE: mezha.media
Yevgeny Demkivsky Author of news Mezha.media and GIK. I write about technologies, cinema and games. Perhaps about games with a little more passion.
“The next big milestone is the beginning of clinical trials, the introduction of these drugs into the human body. We are already approaching that,” Mrdok said.
Isomorphic Labs emerged in 2021 as a daughter of DeepMind after a breakthrough of Alphafold, a system that accurately involves protein structure. The latest version, Alphafold 3, allows you to model the interaction of proteins with DNA, medicines and other molecules, which has made it useful for the development of new drugs.
In 2024, the company signed contracts for joint research with Novartis and Eli Lilly pharmaceuticals. And in April 2025, she raised $ 600 million in investments under the guidance of Thrive Capital.
Isomorphic Labs is working on creating a platform that will combine the experience of pharmacists with machine learning capabilities. The company not only supports partners’ projects, but also initiates the development of medicines in the fields of oncology and immunology. After the early stages of the test, she plans to licensing her development.
Murdock believes that the use of AI will not only accelerate and reduce the cost of development, but also significantly increase the chances of success in clinical trials. In the future, the team seeks to automate the process: to determine the disease and with the help of AI to receive the finished design of the drug.